NDA 208065 · Astrazeneca
Tagrisso
Osimertinib Mesylate · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Nov 13, 2015
Approved uses
10
Original approval plus efficacy supplements
Registered trials
315
53 Phase 3, 82 recruiting
FAERS reports
33,148
31,031 serious, 14,432 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 14, 2026.
TAGRISSO is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.1 , 2.2 ) • the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.2 , 2.2 ) • the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.3 , 2.2 ) • in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.4 , 2.2 ) • the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy. ( 1.5 , 2.2 ) 1.1 Adjuvant Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.2 Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC TAGRISSO is indicated for the treatment of adult...
Mechanism: Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) at approximately 9-fold lower concentrations than wild-type. Two pharmacologically-active metabolites (AZ7550 and AZ5104 circulating at approximately 10% of the parent) with similar inhibitory profiles to osimertinib have been identified in the plasma after oral administration of osimertinib. AZ7550 showed a similar potency to osimertinib, while AZ5104 showed greater potency against exon 19 deletion and T790M mutants...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 14, 2026 Supplement 35 · Efficacy OrphanLetterLabel
- Sep 25, 2024 Supplement 33 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
- Feb 16, 2024 Supplement 30 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Jan 31, 2024 Supplement 29 · Efficacy OrphanLetterLabel
- Dec 18, 2020 Supplement 21 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Dec 9, 2020 Supplement 18 · Efficacy OrphanLabelLetter
- May 23, 2020 Supplement 16 · Efficacy LetterLabel
- Apr 18, 2018 Supplement 8 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Mar 30, 2017 Supplement 6 · Efficacy · priority review OrphanLabelLetter
- Nov 13, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanSummary ReviewLetterLabel
2 products under this application
- TAGRISSO · OSIMERTINIB MESYLATE EQ 40MG BASE · TABLET, ORAL · Prescription
- TAGRISSO · OSIMERTINIB MESYLATE EQ 80MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Osimertinib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
- Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLCPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02474355 · 3,017 participants · Start Sep 18, 2015 · Primary completion Apr 18, 2019
Drug: AZD9291 Dosing · For: Lung Cancer
Sites: Buenos Aires, Argentina; CABA, Argentina; Bedford Park, Australia · 201 sites in all
- Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent SystemNot yet recruiting
NING LIAcademic, hospital or other
NCT06824792 · 3,000 participants (planned) · Start Mar 1, 2025 · Primary completion Feb 29, 2028
Drug: Biologically-informed multi-agent system (Quasar) including targeted drugs Osimertinib, chemotherapy pemetrexed, immunotherapy pembrolizumab et al. approved by China CDE. · For: Advanced Solid Tumors
Sites: Langfang, China
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04487080 · 1,074 participants · Start Sep 30, 2020 · Primary completion Aug 11, 2023
Drug: Amivantamab; Osimertinib and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Goodyear, Arizona; Yuma, Arizona; Long Beach, California · 269 sites in all
DualityBio Inc.Industry
NCT05785741 · 1,000 participants (planned) · Start Aug 17, 2023 · Primary completion Dec 30, 2027
Drug: DB-1310; Trastuzumab and 2 more · For: Advanced Solid Tumor
Sites: Sacramento, California; Santa Monica, California; Coral Gables, Florida · 24 sites in all
AbbVieAbbVie (ABBV)
NCT07005102 · 854 participants (planned) · Start Aug 3, 2025 · Primary completion Nov 2036
Drug: Standard of Care; Telisotuzumab Adizutecan and 4 more · For: Non-Squamous Non-Small Cell Lung Cancer; c-MET
Sites: Chandler, Arizona; Duarte, California; Irvine, California · 65 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07680790 · 850 participants (planned) · Start Sep 8, 2026 · Primary completion Dec 30, 2031
Drug: Iza-bren; Osimertinib and 3 more · For: Non-Small Cell Lung Cancer
Sites: Beverly Hills, California; Fullerton, California; La Jolla, California · 205 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death11,742
- malignant neoplasm progression3,446
- diarrhoea1,744
- fatigue1,121
- drug resistance1,112
- rash988
- off label use830
- decreased appetite829
- disease progression790
- dyspnoea784
- drug ineffective762
- nausea747
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 35 |
| 2016 | 685 |
| 2017 | 1,070 |
| 2018 | 1,424 |
| 2019 | 2,252 |
| 2020 | 3,363 |
| 2021 | 3,455 |
| 2022 | 3,423 |
| 2023 | 4,350 |
| 2024 | 4,988 |
| 2025 | 4,204 |
| 2026 | 3,897 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tagrisso (Osimertinib Mesylate)
2024 spending
$1.63B
Beneficiaries
12,370
96,403 claims
Per beneficiary
$131,537
$553.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $793,479,172 |
| 2021 | $913,265,970 |
| 2022 | $1,081,280,466 |
| 2023 | $1,231,962,204 |
| 2024 | $1,627,109,177 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A, Wang J, Wang Y, et al. · Ann Oncol 2024 · Clinical Trial, Phase III
- Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
Cho BC, Lu S, Felip E, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
Lu S, Kato T, Dong X, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.
Jänne PA, Planchard D, Kobayashi K, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.